Prescribing INGREZZA is now easier than ever
Feel confident in your choice.
INGREZZA coverage is approved for more than 8 of 10 patients nationwide.1
Actor portrayals
Know your INGREZZA prescribing options:
Treatment form
Download and fax the INGREZZA treatment form, which enrolls patients in the Neurocrine Access Support program and serves as their INGREZZA prescription through one of our national specialty pharmacies
CoverMyMeds
Step-by-step instructions to initiate treatment and enroll patients in the Neurocrine Access Support program by using the INGREZZA digital treatment form. CoverMyMeds can also provide support for prior authorization (PA) requests
ePrescribe
You can ePrescribe to our dedicated network of pharmacies
Navigating the PA process
CoverMyMeds can help streamline the PA process for you and help providers and pharmacists get patients the medication they need. Complete the PA that may be necessary to secure INGREZZA coverage with your patient’s insurance provider by clicking the button below to start a request.
Our Regional Patient Access Managers (RPAMs) can help you navigate the PA process.
A dedicated network of pharmacies
Choosing the right pharmacy matters. INGREZZA is available through a carefully selected network of pharmacies.
Pharmacy network
- Amber Specialty Pharmacy
- CVS Specialty
- Orsini Specialty Pharmacy
- PANTHERx RARE
- Walgreens Specialty Pharmacy*
- Genoa Healthcare Pharmacies
- Select local pharmacies
- National, regional, and local Long-Term Care pharmacies
*If a prescription is sent to a Walgreens Specialty Pharmacy, please contact the store directly.
Delivery
By choosing one of our network specialty pharmacies, your patient can benefit from the convenience of having INGREZZA delivered directly to them. This assists with timely and streamlined access to their medication. Or, if preferred, patients can also opt to pick up their prescription at their local pharmacy, providing flexibility to suit their needs.
Third party trademarks are property of their respective owners.
Reference
1. Measured by NDC. Data on file as of Q1 2025. Neurocrine Biosciences, Inc.
